



February 5, 2026

Company name: Mitsubishi Chemical Group Corporation
Representative: Manabu Chikumoto
Representative Corporate Executive Officer,
President & Chief Executive Officer
Listed on The Prime Market TSE (stock
code:4188)
Contact: [Press inquiries]
Corporate Communications Office
Tel: (+81) (0)3-6748-7140
[IR inquiries]
Investor Relations Office
Tel: (+81) (0)3-6748-7120

Notice On Revision to Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2026

Mitsubishi Chemical Group Corporation has revised the forecast that it announced on October 31, 2025 for the fiscal year ending March 31, 2026 (fiscal 2025), as follows.

1. Consolidated financial results forecast for fiscal 2025 (April 1, 2025 - March 31, 2026)

(Billions of yen; unless otherwise noted)

	Sales revenue	Core operating income	Operating income	Net income	Net income attributable to owners of the parent	Basic earnings per share (yen)
Previous forecast (A) (announced on October 31, 2025)	3,672.0	250.0	176.0	189.9	125.0	91.21
Revised forecast (B)	3,672.0	250.0	70.0	114.8	47.0	34.29
Difference (B – A)	-	-	(106.0)	(75.1)	(78.0)	
Difference (%)	-	-	(60.2)	(39.5)	(62.4)	
Reference: Results for fiscal 2025	3,947.6	228.8	141.6	105.6	45.0	31.64

Notes:

- The forecast for net income before taxes has been changed from ¥138.0 billion to ¥36.0 billion.
- Core operating income is operating income (loss) after excluding certain gains and expenses attributable to non-recurring factors.
- Upon the approval at MCG's Ordinary General Meeting of Shareholders held on June 25, 2025 with regard to the absorption-type split agreement to transfer all shares and related assets of Mitsubishi Tanabe Pharma Corporation (hereinafter "MTPC"), MTPC and its subsidiaries and affiliates have been transferred on July 1, 2025. MTPC and its subsidiaries and affiliates have been classified as discontinued operations since the beginning of the fiscal year, and sales revenue, core operating income, operating income and income before taxes, and for the consolidated financial results forecast for fiscal 2025 and financial results for fiscal 2024 represent the amounts of continued operations excluding discontinued operations.

Mitsubishi Tanabe Pharma Corporation changed its corporate name to Tanabe Pharma Corporation as of December 1, 2025.

2. Reason for revision

We predict that sales revenue and core operating income for fiscal 2025 are expected to remain unchanged from the previously announced forecast. Operating income, net income, and net income attributable to owners of the parent are anticipated to fall behind the previously announced forecast, as the Company expects to record additional non-recurring losses related to various structural reform measures, including a loss associated with the business withdrawal described in the "Notice of Withdrawal from Coke and Carbon Materials Business" announced on February 2, 2026.

Reference:**Core operating income by segment (April 1, 2025 - March 31, 2026)**

(Billions of yen)

	Revised forecast	Previous forecast	Difference
Specialty Materials	65.0	65.0	-
MMA & Derivatives	(1.0)	(1.0)	-
Basic Materials & Polymers	(1.0)	(1.0)	-
Industrial Gases	189.0	189.0	-
Others	(2.0)	(2.0)	-
Total	250.0	250.0	-

Forward-Looking Statements

The forward-looking statements are based largely on the Company's expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond the Company's control. Actual results could differ materially due to numerous factors, including, without limitation, market conditions, and the effect of industry competition.